Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 33c; Offers FY23 EPS Guidance

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.26, $0.33 better than the analyst estimate of $0.93. Revenue for the quarter came in at $66.3 million versus the consensus estimate of $63.29 million.

GUIDANCE:

Eagle Pharmaceuticals sees FY2023 EPS of $4.20-$4.53, versus the consensus of $4.21.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49